NCT05673980

Oral Vitamin D2 for Prevention of COVID-19

A Randomized Controlled Clinical Trial of Oral Vitamin D2 for the Prevention of COVID-19

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 218 (estimated)
• Sponsor: Peking University Third Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

A total of 218 participants will be included in this study, and will be randomly assigned 1:1 to the group taking vitamin D2 and the group not taking vitamin D2. Participants in the group taking vitamin D2 orally will receive 200,000 IU of vitamin D2 on the first day of the trial, and again two weeks later (200,000 IU) . The group that will not receive vitamin D2 will not receive any intervention. The whole trial will laste four weeks.

Detailed description

This study is a randomized controlled multicenter clinical trial. Participants who meet the inclusion criteria can be included in this trial after signing informed consent. A total of 218 participants will be included in this study, and will be randomly assigned 1:1 to the group taking vitamin D2 and the group not taking vitamin D2. Participants in the group taking vitamin D2 orally will receive 200,000 IU of vitamin D2 on the first day of the trial, and again two weeks later (200,000 IU) . The group that will not receive vitamin D2 will not receive any intervention. The whole trial will laste four weeks. Throughout the trial, participants' nucleic acid or antigen results, 25(OH)D concentrations, etc., need to be tested.

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	Vitamin D2	Participants in the vitamin D2 group received 200,000 IU of vitamin D2 orally on the first day of the trial and again two weeks later
OTHER	placebo	This group will not do any intervention

Timeline

• Start date: 2022-12-18
• Primary completion: 2023-01-19
• Completion: 2023-02-20
• First posted: 2023-01-06
• Last updated: 2023-01-06

Locations

1 site across 1 country: China